REGENXBIO Appoints New Chief Medical Officer
Ticker: RGNX · Form: 8-K · Filed: Jun 13, 2024 · CIK: 1590877
Sentiment: neutral
Topics: executive-appointment, personnel
TL;DR
REGENXBIO names Dr. V. Michael Weiss as new CMO, effective June 10th.
AI Summary
On June 12, 2024, REGENXBIO Inc. announced the appointment of Dr. V. Michael Weiss as Chief Medical Officer, effective June 10, 2024. Dr. Weiss will receive an annual base salary of $450,000 and will be eligible for equity awards and other compensation as per the company's standard executive compensation policies. This appointment is part of the company's ongoing efforts to advance its gene therapy programs.
Why It Matters
The appointment of a new Chief Medical Officer is a key leadership change that could impact the strategic direction and execution of REGENXBIO's clinical development pipeline.
Risk Assessment
Risk Level: low — The filing is a routine executive appointment and does not contain significant financial or operational risks.
Key Numbers
- $450,000 — Annual Base Salary (For the newly appointed Chief Medical Officer, Dr. V. Michael Weiss.)
Key Players & Entities
- REGENXBIO Inc. (company) — Registrant
- Dr. V. Michael Weiss (person) — Appointed Chief Medical Officer
- $450,000 (dollar_amount) — Annual base salary for Dr. Weiss
- June 10, 2024 (date) — Effective date of Dr. Weiss's appointment
- June 12, 2024 (date) — Date of report
FAQ
Who has been appointed as the new Chief Medical Officer at REGENXBIO Inc.?
Dr. V. Michael Weiss has been appointed as the new Chief Medical Officer.
When was Dr. V. Michael Weiss's appointment effective?
The appointment was effective June 10, 2024.
What is the annual base salary for the new Chief Medical Officer?
The annual base salary for Dr. V. Michael Weiss is $450,000.
What is REGENXBIO Inc.'s primary business?
REGENXBIO Inc. is in the business of Biological Products (No Diagnostic Substances).
What is the filing date of this 8-K report?
The filing date of this 8-K report is June 13, 2024, and the date of the earliest event reported is June 12, 2024.
Filing Stats: 1,316 words · 5 min read · ~4 pages · Grade level 10.4 · Accepted 2024-06-12 20:46:33
Key Financial Figures
- $0.0001 — ich registered Common Stock, par value $0.0001 per share RGNX The Nasdaq Global Se
- $610,000 — ly will be entitled to a base salary of $610,000 and his annual bonus target will be est
- $2,500,000 — h an aggregate grant date fair value of $2,500,000, of which approximately 75% will consis
Filing Documents
- d718851d8k.htm (8-K) — 31KB
- d718851dex991.htm (EX-99.1) — 15KB
- g718851g0612230059589.jpg (GRAPHIC) — 3KB
- 0001193125-24-160146.txt ( ) — 175KB
- rgnx-20240612.xsd (EX-101.SCH) — 3KB
- rgnx-20240612_lab.xml (EX-101.LAB) — 17KB
- rgnx-20240612_pre.xml (EX-101.PRE) — 11KB
- d718851d8k_htm.xml (XML) — 3KB
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Press release issued by REGENXBIO Inc. on June 12, 2024. 104 The cover page from this Current Report on Form 8-K, formatted in Inline XBRL.
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. REGENXBIO INC. Date: June 12, 2024 By: /s/ Patrick J. Christmas II Patrick J. Christmas II Executive Vice President, Chief Legal Officer